Drug Reduces MS Likelihood
(Ivanhoe Newswire) – According to a recent study, people who received injections of the multiple sclerosis (MS) drug interferon beta-1a directly after noticing signs of possible MS were less likely to progress into definite MS compared to those who switched to interferon beta-1a from placebo.
Although it is not currently available in the United States, the trial was conducted with the human serum albumin-free formulation of interferon beta-1a, which is available in all European Union countries, Australia, Switzerland, Canada, and a number of countries in Africa, the Middle East, Latin America, and Asia.
"While we've known it's beneficial to start MS drugs as soon as possible, this is the first trial to show a benefit of early injections of interferon beta-1a treatment at three years," Mark Freedman, M.S., with the University of Ottawa in Ontario, Canada, and a Fellow of the American Academy of Neurology, was quoted as saying.
The clinical trial took three years and involved 517 people who had one clinical episode suggestive of a demyelinating event, such as tingling, muscle weakness, or problems with balance, coupled with having at least two silent brain lesions detected by a MRI scan.
SOURCE: American Academy of Neurology, April 2012
http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=29267
Drug Reduces MS Likelihood | Medical News and Health Information
(Ivanhoe Newswire) – According to a recent study, people who received injections of the multiple sclerosis (MS) drug interferon beta-1a directly after noticing signs of possible MS were less likely to progress into definite MS compared to those who switched to interferon beta-1a from placebo.
Although it is not currently available in the United States, the trial was conducted with the human serum albumin-free formulation of interferon beta-1a, which is available in all European Union countries, Australia, Switzerland, Canada, and a number of countries in Africa, the Middle East, Latin America, and Asia.
"While we've known it's beneficial to start MS drugs as soon as possible, this is the first trial to show a benefit of early injections of interferon beta-1a treatment at three years," Mark Freedman, M.S., with the University of Ottawa in Ontario, Canada, and a Fellow of the American Academy of Neurology, was quoted as saying.
The clinical trial took three years and involved 517 people who had one clinical episode suggestive of a demyelinating event, such as tingling, muscle weakness, or problems with balance, coupled with having at least two silent brain lesions detected by a MRI scan.
SOURCE: American Academy of Neurology, April 2012
http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=29267
Drug Reduces MS Likelihood | Medical News and Health Information
No comments:
Post a Comment